电邮这篇文章 Local cytokine therapy in a comprehensive treatment of HPV-associated cervical diseases
- 作者: Abakarova P.R1, Prilepskaya V.N1, Mezhevitinova E.A1, Donnikov A.E1
-
隶属关系:
- V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation
- 期: 卷 21, 编号 1 (2019)
- 页面: 28-32
- 栏目: Articles
- URL: https://ogarev-online.ru/2079-5831/article/view/30127
- DOI: https://doi.org/10.26442/20795696.2019.1.190284
- ID: 30127
如何引用文章
全文:
详细
Aim. To analyze an efficacy of monotherapy and combined therapy (an immunomodulator + radio wave ablation) in patients with low-grade squamous intraepithelial lesion (L-SIL) caused by HPV infection. Materials and methods. The study included 210 women with human papillomavirus infection which was identified using real-time polymerase chain reaction (PCR). All women underwent a comprehensive examination which included history taking, general and gynecological examinations, extended colposcopy and a bacterioscopy of Gram-stained vaginal smears. A quantitative determination of vaginal microflora composition by PCR was carried out. Conclusion on either inflammatory response is present or absent was made on the basis of an inflammation index magnitude: with a value of more than 60% indicating a presence of local inflammation signs. Based on cervical cytology data a group consisting of 79 women who had L-SIL was formed. Patients were divided into 2 subgroups: the main one (n=45) who received combined treatment with radio wave ablation + an immunomodulator and a control one (n=34) who received only local monodestruction of L-SIL foci followed etiotropic treatment. Results and discussion. An efficacy of combined treatment which included radio wave ablation + an immunomodulator was higher compared to monodestruction only - 86.7% vs 64,7% respectively. It is important that by 6th month of follow-up a relapse of human papillomavirus infection occurred in 4.5 and 23.5% of patients of main and control groups respectively. Local inflammation was assessed as positive with an inflammation index of more than 60%. So after 6 months of follow-up this indicator decreased by 83.3 and 54.2% in the 1st and 2nd groups respectively. Clinical manifestations of an inflammatory process in the cervix was observed only with CIN recurrence. In addition, combined therapy provides a higher rate of human papillomavirus elimination at 6 months and faster cervix epithelization followed treatment by ablation.
作者简介
Patimat Abakarova
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian FederationMClSc, PhD, Researcher of the Scientific and Polyclinic Department 4, Akademika Oparina st., Moscow, 117997, Russian Federation
Vera Prilepskaya
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation
Email: VPrilepskaya@mail.ru
MD, PhD, Professor, Deputy director for Science, Head of the Scientific and Polyclinic Department 4, Akademika Oparina st., Moscow, 117997, Russian Federation
Elena Mezhevitinova
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian FederationMD, PhD, DSc, Leading Researcher of the Scientific and Polyclinic Department 4, Akademika Oparina st., Moscow, 117997, Russian Federation
Andrei Donnikov
V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian FederationMClSc, PhD, Head of the Laboratory of molecular and genetic methods 4, Akademika Oparina st., Moscow, 117997, Russian Federation
参考
- Сухих Г.Т., Прилепская В.Н. Профилактика рака шейки матки: руководство для врачей. 3-е изд. М.: МЕДпресс-информ, 2012. [Sukhikh G.T., Prilepskaya V.N. Profilaktika raka sheiki matki: rukovodstvo dlia vrachei. 3-e izd. Moscow: MEDpress-inform, 2012 ]
- Bruni L, Diaz M, Castellsagué X et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological i ndings. J Infect Dis 2010; 202 (12): 1789-99.
- Munoz N, Bosch F, Sanjos S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518-27.
- Tang Y, Zheng L, Yang S et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women. Virology J 2017; 14: 84.
- Smith J.S, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasivе cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621-32.
- Бебнева Т.Н. Некоторые аспекты папилломавирусной инфекции. Гинекология. 2007; 9 (1): 19-22. [Bebneva T.N. Nekotorye aspekty papillomavirusnoi infektsii. Gynecology. 2007; 9 (1): 19-22.]
- Долгушина В.Ф., Ахматова А.Н., Телешева Л.Ф., Абрамовских О.С. Персистенция папилломавирусной инфекции у женщин с хроническим цервицитом. Уральский мед. журн. 2010; 3 (68): 91-4. [Dolgushina V.F., Akhmatova A.N., Telesheva L.F., Abramovskikh O.S. Persistentsiia papillomavirusnoi infektsii u zhenshchin s khronicheskim tservitsitom. Ural'skii med. zhurn. 2010; 3 (68): 91-4 ]
- Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol Oncol 2007; 107: 2 (Suppl. 1): 14-9. https://doi. org/10.1016/j.ygyno.2007.07.069
- Weaver B, Shew M, Qadadri B et al. Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J Med Virol 2011; 83 (8): 1362-9.
- Манухин И.Б., Минкина Г.Н., Левченко Г.М., Гурин В.Е. Патогенетическое обоснование комплексного лечения папилломавирусной инфекции шейки матки. Журн. акушерства и женских болезней. Спец. выпуск. 1998. [Manukhin I.B., Minkina G.N., Levchenko G.M., Gurin V.E. Patogeneticheskoe obosnovanie kompleksnogo lecheniia papillomavirusnoi infektsii sheiki matki. Zhurn. akusherstva i zhenskikh boleznei. Spets. vypusk. 1998 ]
- Сухих Г.Т., Матвеева Н.К., Аполихина И.А. и др. Показатели иммунитета у больных с папилломавирусной инфекцией гениталий. Акушерство и гинекология. 2002; 2: 20-5. [Sukhikh G.T., Matveeva N.K., Apolikhina I.A. et al. Pokazateli immuniteta u bol'nykh s papillomavirusnoi infektsiei genitalii. Akusherstvo i ginekologiia. 2002; 2: 20-5 ]
- Роговская С.И., Жданов А.В., Логинова Л.С. и др. Состояние системы интерферонов у женщин с папилломавирусной инфекцией гениталий при использовании иммуномодулирующей терапии. Бюл. эксперим. биологии и медицины. 2002; 131 (11): 538-42. [Rogovskaia S.I., Zhdanov A.V., Loginova L.S. et al. Sostoianie sistemy interferonov u zhenshchin s papillomavirusnoi infektsiei genitalii pri ispol'zovanii immunomoduliruiushchei terapii. Biul. eksperim. biologii i meditsiny. 2002; 131 (11): 538-42 ]
- Seresini S, Origoni M, Lillo F at al. IFN-gamma produced by human papilloma virus-18 E6-spesific CD4+ T-cells predicts the clinical outcome after surgery with high-grade cervical lesions. J Immunol 2007; 179: 7176-83.
- Дубенский В.В., Кузнецов В.П., Беляев Д.Л., Слюсарь Н.Н. Эффективность иммунокоррекции цитокинами при лечении папилломавирусной инфекции. Журн. микробиологии, эпидемиологии и иммунобиологии. 2001; 5: 54-8. [Dubenskii V.V., Kuznetsov V.P., Beliaev D.L., Sliusar' N.N. Effektivnost' immunokorrektsii tsitokinami pri lechenii papillomavirusnoi infektsii. Zhurn. mikrobiologii, epidemiologii i immunobiologii. 2001; 5: 54-8 ]
- Кореева В.Н., Доброхотова Ю.Э. Применение локальной цитокинотерапии в акушерско-гинекологической практике. Рос. вестн. акушера-гинеколога. 2013; 5: 99-104. [Koreeva V.N., Dobrokhotova Iu.E. Primenenie lokal'noi tsitokinoterapii v akushersko-ginekologicheskoi praktike. Ros. vestn. akushera-ginekologa. 2013; 5: 99-104 ]
- Kanodia S, Da Silva D.M, Kast W.M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122: 247-59.
补充文件
